尿液蛋白组合可预测活动性狼疮肾炎及利妥昔单抗治疗反应
研究纳入197例SLE患者和48例健康对照,检测尿液中六种蛋白浓度,发现五种蛋白组合能良好预测活动性狼疮肾炎(AUC 0.898),六种蛋白组合可预测利妥昔单抗治疗12个月反应(AUC 0.818)。
要点
- 尿转铁蛋白、AGP-1、MCP-1和sVCAM-1在SLE患者中显著高于健康对照。
- 五种尿蛋白组合(LPGDS、转铁蛋白、铜蓝蛋白、MCP-1、sVCAM-1)预测活动性LN的AUC为0.898。
- 六种尿蛋白组合预测利妥昔单抗治疗12个月反应的AUC为0.818。
核心结论
- 尿液蛋白组合可用于识别成人SLE患者的活动性狼疮肾炎,并可能预测利妥昔单抗治疗反应。
研究设计与样本
- 研究纳入197例SLE患者和48例健康对照,收集尿液样本,用MILLPLEX® Assays在MAGPIX Luminex平台上定量六种蛋白浓度,并用二元逻辑回归分析蛋白水平与活动性肾脏受累及利妥昔单抗治疗反应的关系。
主要发现
- 与健康对照相比,SLE患者尿中转铁蛋白(P <0.005)、AGP-1(P <0.0001)、MCP-1(P <0.001)和sVCAM-1(P <0.005)水平显著升高。
- 与无活动性LN的SLE患者相比,活动性LN患者尿中转铁蛋白、AGP-1、铜蓝蛋白、MCP-1和sVCAM-1水平均显著升高(均P <0.0001)。
- 五种尿蛋白(LPGDS、转铁蛋白、铜蓝蛋白、MCP-1、sVCAM-1)组合预测活动性LN的AUC为0.898。
- 六种尿蛋白(LPGDS、转铁蛋白、AGP-1、铜蓝蛋白、MCP-1、sVCAM-1)组合预测利妥昔单抗治疗12个月反应的AUC为0.818。
临床怎么用
- 对于SLE患者,可考虑检测尿液蛋白组合(LPGDS、转铁蛋白、铜蓝蛋白、MCP-1、sVCAM-1等)以辅助无创评估活动性狼疮肾炎。
- 尿液蛋白组合可能有助于预测成人SLE患者对利妥昔单抗的治疗反应,但需前瞻性研究确认。
局限性
- 研究结论需前瞻性研究进一步确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: ∼30% of patients with SLE develop LN. Presence and/or severity of LN are currently assessed by renal biopsy, but biomarkers in serum or urine samples may provide an avenue for non-invasive routine testing. We aimed to validate a urinary protein panel for its ability to predict active renal involvement in SLE. METHODS: A total of 197 SLE patients and 48 healthy controls were recruited, and urine samples collected. Seventy-five of the SLE patients had active LN and 104 had no or inactive renal disease. Concentrations of lipocalin-like prostaglandin D synthase (LPGDS), transferrin, alpha-1-acid glycoprotein (AGP-1), ceruloplasmin, monocyte chemoattractant protein 1 (MCP-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) were quantified by MILLIPLEX® Assays using the MAGPIX Luminex platform. Binary logistic regression was conducted to examine whether proteins levels associate with active renal involvement and/or response to rituximab treatment. RESULTS: Urine levels of transferrin (P <0.005), AGP-1 (P <0.0001), MCP-1 (P <0.001) and sVCAM-1 (P <0.005) were significantly higher in SLE patients when compared with healthy controls. Furthermore, levels of transferrin, AGP-1, ceruloplasmin, MCP-1 and sVCAM-1 (all P <0.0001) were higher in SLE patients with active LN when compared with patients without active LN. A combination of five urine proteins, namely LPGDS, transferrin, ceruloplasmin, MCP-1 and sVCAM-1 was a good predictor of active LN (AUC 0.898). A combined model of LPGDS, transferrin, AGP-1, ceruloplasmin, MCP-1 and sVCAM-1 predicted response to rituximab treatment at 12 months (AUC 0.818). CONCLUSIONS: Findings support the use of a urinary protein panel to identify active LN and potentially predict response to treatment with rituximab in adult SLE patients. Prospective studies are required to confirm findings.
引用
- Davies JC, Carlsson E, Midgley A, et al. A panel of urinary proteins predicts active lupus nephritis and response to rituximab treatment. Rheumatology (Oxford). 2021. PMID: 33313921. doi:10.1093/rheumatology/keaa851
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。